Authors
Di Liu, Na Yuan, Guimei Yu, Daqing Nie
Published in
Archivum immunologiae et therapiae experimentalis. Volume 74. Issue 1. Jan 01, 2026. Epub Nov 10, 2026.
Abstract
Radiographic progression in rheumatoid arthritis (RA) reflects irreversible joint damage. Whether different classes of biologic disease-modifying antirheumatic drugs (bDMARDs) offer comparable structural protection remains uncertain. To compare six bDMARD classes (tumor necrosis factor [TNF]-α inhibitors, interleukin [IL]-17 inhibitors, T-cell co-stimulation modulators, B-cell depleting agents, IL-6 receptor antagonists, and IL-23 inhibitors) in suppressing radiographic progression in RA. PubMed, Embase, Web of Science, and CENTRAL were searched to 31 December 2025 for randomized controlled trials (RCT); change in modified Total Sharp Score (mTSS) at 12 months was the primary outcome. A Bayesian random-effects network meta-analysis was fitted, with SUCRA-based ranking. 27 RCTs (11,650 patients) were included. All six classes significantly inhibited mTSS progression versus placebo. Relative to TNF-α inhibitors (TNF-i), greater inhibition was seen with B-cell depleting agents (mean difference [MD] = -18.46, 95% CI -20.86 to -16.06), IL-23 inhibitors (MD = -18.14, 95% CI -21.11 to -15.16), IL-17 inhibitors (MD = -15.67), T-cell co-stimulation modulators (MD = -14.99) and IL-6 receptor antagonists (MD = -13.73); the first two were also superior to IL-6 receptor antagonists. For bone erosion (13 RCTs), IL-17, B-cell depleting, IL-6 receptor and T-cell agents, but not IL-23 inhibitors, were superior to TNF-i. For ACR20 (20 RCTs), IL-23 (OR = 2.75, 95% CI 1.31-5.76), IL-6 (OR = 2.12) and IL-17 (OR = 1.86) inhibitors were superior to TNF-i. Serious adverse events (10 RCTs) did not differ from placebo. B-cell depleting agents and IL-23 inhibitors ranked highest; as several comparisons rest on few trials, this ordering is hypothesis generating.
PMID:
43007285
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0